BioArctic

BioArctic Tax Expense

The Income Tax Expense of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 233.26 M SEK. In the previous year, Income Tax Expense was -12.44 M SEK — a change of -1,975.09% (higher).

Tax Expense

233.26 MSEK

YoY

-1,975.09%

Last updated:

Income Tax Expense of BioArctic is 2025 233.26 M SEK. Income Tax Expense of BioArctic was 2024 -12.44 M SEK. It decreases by -1,975.09% higher compared to the previous year.

The BioArctic Tax Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tax Expense
Date
Tax Expense
Jan 1, 2018
107.99 M SEK
Jan 1, 2019
24.51 M SEK
Jan 1, 2020
-18.17 M SEK
Jan 1, 2021
-20.72 M SEK
Jan 1, 2022
11,000.00 SEK
Jan 1, 2023
47.24 M SEK
Jan 1, 2024
-12.44 M SEK
Jan 1, 2025
233.26 M SEK
The BioArctic Tax Expense history
YEARTax ExpenseYoY
233.26 MSEK-1,975.09%
-12.44 MSEK-126.34%
47.24 MSEK+429,327.27%
11,000.00SEK-100.05%
-20.72 MSEK+14.03%
-18.17 MSEK-174.16%
24.51 MSEK-77.31%
107.99 MSEK+2,281.80%
4.53 MSEK-72.61%
16.56 MSEK+1,431.54%
1.08 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Income Tax Expense of BioArctic is 233.26 M SEK in 2025.

Income Tax Expense of BioArctic changed from -12.44 M SEK to 233.26 M SEK, representing a -1,975.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Income Tax Expense BioArctic since 2006 – with annual values, charts, and detailed analysis.

Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.

Income Tax Expense's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BioArctic

All Key Metrics — BioArctic